Annex Advisory Services LLC boosted its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 794.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 111,413 shares of the medical research company's stock after purchasing an additional 98,954 shares during the quarter. Annex Advisory Services LLC's holdings in Amgen were worth $46,962,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also recently bought and sold shares of the company. BlackRock Inc. boosted its holdings in shares of Amgen by 4.8% in the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company's stock worth $17,874,974,000 after purchasing an additional 2,261,544 shares in the last quarter. State Street Corp lifted its position in Amgen by 38.2% in the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company's stock worth $15,283,363,000 after buying an additional 11,656,755 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Amgen by 12.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company's stock worth $1,952,156,000 after buying an additional 605,928 shares in the last quarter. Bank of America Corp DE bought a new position in Amgen during the second quarter valued at approximately $1,831,903,000. Finally, Invesco Ltd. grew its position in Amgen by 7.2% during the fourth quarter. Invesco Ltd. now owns 4,788,460 shares of the medical research company's stock valued at $1,567,311,000 after acquiring an additional 321,173 shares during the last quarter. 76.50% of the stock is owned by institutional investors.
Amgen Price Performance
Shares of NASDAQ AMGN opened at $432.49 on Friday. Amgen Inc. has a 1 year low of $288.00 and a 1 year high of $447.03. The stock has a market capitalization of $233.82 billion, a P/E ratio of 19.40, a P/E/G ratio of 3.18 and a beta of 0.41. The company's 50-day moving average is $415.54 and its 200 day moving average is $374.76. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13.
Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. The business had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. Amgen's quarterly revenue was up 9.5% compared to the same quarter last year. During the same period last year, the business posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, sell-side analysts expect that Amgen Inc. will post 22.94 earnings per share for the current year.
Amgen Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date was Friday, August 21st. Amgen's dividend payout ratio (DPR) is presently 62.65%.
Analyst Upgrades and Downgrades
A number of brokerages have recently weighed in on AMGN. Bank of America boosted their price objective on shares of Amgen from $312.00 to $317.00 and gave the stock an "underperform" rating in a report on Wednesday, August 5th. Oppenheimer reaffirmed an "outperform" rating on shares of Amgen in a research note on Wednesday, September 23rd. Guggenheim reduced their target price on shares of Amgen from $388.00 to $378.00 and set a "neutral" rating on the stock in a report on Tuesday. Robert W. Baird increased their target price on shares of Amgen from $215.00 to $230.00 and gave the company an "underperform" rating in a report on Wednesday, August 5th. Finally, HSBC downgraded shares of Amgen from a "buy" rating to a "hold" rating and lowered their price target for the stock from $445.00 to $425.00 in a research note on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Amgen has an average rating of "Hold" and an average target price of $387.93.
Check Out Our Latest Research Report on AMGN
Insider Buying and Selling
In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Rachna Khosla sold 2,000 shares of the firm's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total value of $825,140.00. Following the transaction, the senior vice president directly owned 6,404 shares of the company's stock, valued at $2,642,098.28. This represents a 23.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is currently owned by company insiders.
Amgen Company Profile
(
Free Report)
Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.
Amgen's portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.
See Also
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
